一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

What is Posaconazole?

Mar 29,2022

DESCRIPTION 

Posaconazole (Nofaxil, SCH-56592) is a triazole derivative with a chemical structure similar to itraconazole. The structures of both azoles contain extended piperazine-phenyl-triazole side-chains, but posaconazole is composed of a furan ring with fluorine substituted for chlorine. Like other compounds in the azole class, posaconazole disrupts fungal ergosterol biosynthesis through inhibition 14a-lanosterol demethylation. Currently, the only available preparation is an immediate-release oral suspension containing polysorbate 80 as an emulsifying agent. 

Posaconazole demonstrates potent activity against Candida spp., Cryptococcus spp., dimorphic fungi, and filamentous fungi, including Aspergillus as well as Zygomycetes. It has Food and Drug Administration (FDA) approval for prophylaxis of invasive fungal infection in hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD) and patients with hematologic malignancies and prolonged neutropenia. It is also FDA approved for treatment of oropharyngeal candidiasis. In Europe, posaconazole is additionally approved for the following fungal infections refractory to amphotericin B and/or itraconazole: aspergillosis, fusariosis, chromoblastomycosis, mycetoma, and coccidioidomycosis.

MECHANISM OF DRUG ACTION 

Posaconazole is a triazole drug which inhibits cytochrome P450- dependent C14-a sterol demethylase, a key enzyme in the biosynthesis of fungal ergosterol. Disruption of this step results in depletion of ergosterol from the fungal cell membrane. As the ergosterol content decreases and methylated sterol intermediates accumulate, membrane permeability increases and growth is inhibited. If severe, these changes may result in cell death.

TOXICITY

Similar to the other drugs from the triazole class, posaconazole appears to be well-tolerated. The most common adverse effects are mild and include gastrointestinal complaints, rash, facial flushing, dry mouth, and headache. Gastrointestinal symptoms (diarrhea, nausea, and vomiting) were reported in 15% of patients receiving posaconazole Table 136.4 Potential posaconazole drug interactions. Posaconazole may increase drug concentration Antiarrhythmics – quinidine Antibiotics – rifabutin Antiepileptics – phenytoin Antimalarials – halofantrine Antipsychotics – pimozide Antiretrovirals – etravirine Antihistamine – astemizole (off market), terfenadine (off market) Benzodiazepines – midazolam Calcium channel blockers – amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil Ergot alkaloids – dihydroergotamine, ergoloid mesylates, ergonovine, ergotamine, methylergonovine, methysergide Immunosuppressants – ciclosporin, sirolimus, tacrolimus Serotonic receptor antagonists – cisapride (off market) Statins – atorvastatin, lovastatin, simvistatin Vinca alkaloids – vinblastine, vincristine, vincristine liposome, vinorelbine Drugs that may decrease posaconazole concentration Antiepileptics – phenytoin H2-blockers – cimetidine 1866 Systemic Azoles for persistent febrile neutropenia or refractory invasive fungal infection. Rash or other skin disorders occurred in 3% of these patients, but did not result in discontinuation of the drug. Like other azoles, hepatic toxicity has been infrequently described. Therefore, monitoring of liver function tests is recommended before and during treatment. Very rarely, prolongation of QT or QTc interval and torsades de pointes have been reported. 

Posaconazole is pregnancy category C and has not been studied in pregnant women. Administration of another azole, fluconazole, during pregnancy was associated with congenital birth defects, including craniofacial, skeletal, and cardiac anomalies. Posaconazole is not recommended for pregnant women or nursing mothers unless the potential benefit outweighs the risk.

  • Related articles
  • Related Qustion
See also
4

Capreomycin is an important reserve antibiotic for the treatment of tuberculosis and has been used for this purpose for more than 40 years. It is a naturally produced cyclic polypeptide first isolated in 1959 from Streptomyces capreolus at....

Mar 29,2022API
4

Cycloserine was isolated by independent investigators in the early 1950s from cultures of Streptomyces orchidaceus and S. garyphalus. Racemic cycloserine can be synthesized but the active antibiotic, the D-stereoisomer, is usually produced....

Mar 29,2022API

Posaconazole

171228-49-2

Posaconazole manufacturers

  • Posaconazole
  • 171228-49-2 Posaconazole
  • 2026-06-22
  • CAS:171228-49-2
  • Min. Order: 2Kg/Bag
  • Purity: USP
  • Supply Ability: 20 tons
  • Posaconazole
  • 171228-49-2 Posaconazole
  • 2026-06-12
  • CAS:171228-49-2
  • Min. Order: 1g
  • Purity: More Than 99%
  • Supply Ability: 100kg/Month

祁连县| 高青县| 闽清县| 新泰市| 和龙市| 津市市| 通州区| 筠连县| 临颍县| 荔波县| 舒城县| 巢湖市| 平遥县| 金堂县| 巫溪县| 惠州市| 扎赉特旗| 马龙县| 金川县| 虞城县| 通州区| 长葛市| 辽中县| 盐边县| 称多县| 铁岭市| 昌乐县| 越西县| 内丘县| 禹州市| 兴化市| 马边| 湄潭县| 阿坝| 客服| 北安市| 太康县| 临汾市| 建昌县| 绥宁县| 卓资县|